Case Reports in Endocrinology (Jan 2025)

Successful Treatment With Evocalcet Against Familial Hypocalciuric Hypercalcemia Type 3 (FHH3) Identified by AP2S1 Gene Mutation (p.Arg15Leu)

Ai Chida,
Yutaka Hasegawa,
Toshie Segawa,
Daisuke Yamabe,
Hirotaka Yan,
Yusuke Chiba,
Hiraku Chiba,
Hirofumi Kinno,
Tomoyasu Oda,
Yoshihiko Takahashi,
Koji Nata,
Yasushi Ishigaki

Affiliations

Ai Chida: Division of Diabetes, Metabolism and Endocrinology
Yutaka Hasegawa: Division of Diabetes, Metabolism and Endocrinology
Toshie Segawa: Division of Diabetes, Metabolism and Endocrinology
Daisuke Yamabe: Department of Orthopaedic Surgery
Hirotaka Yan: Department of Orthopaedic Surgery
Yusuke Chiba: Department of Orthopaedic Surgery
Hiraku Chiba: Division of Diabetes, Metabolism and Endocrinology
Hirofumi Kinno: Division of Diabetes, Metabolism and Endocrinology
Tomoyasu Oda: Division of Diabetes, Metabolism and Endocrinology
Yoshihiko Takahashi: Division of Diabetes, Metabolism and Endocrinology
Koji Nata: Division of Medical Biochemistry
Yasushi Ishigaki: Division of Diabetes, Metabolism and Endocrinology

DOI: https://doi.org/10.1155/crie/9514578
Journal volume & issue: Vol. 2025

Abstract

Conclusion: Evocalcet may be a promising therapeutic candidate for symptomatic FHH3.

Published in Case Reports in Endocrinology

ISSN: 2090-6501 (Print); 2090-651X (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the endocrine glands. Clinical endocrinology
Website: https://onlinelibrary.wiley.com/journal/7520

About the journal